Qiagen (NASDAQ:QGEN) had its price target lifted by Morgan Stanley from $38.00 to $39.00 in a research note published on Wednesday. Morgan Stanley currently has an overweight rating on the stock.

A number of other brokerages also recently issued reports on QGEN. Commerzbank reiterated a buy rating on shares of Qiagen in a research report on Monday, September 17th. Zacks Investment Research downgraded Qiagen from a hold rating to a sell rating in a research report on Tuesday, July 3rd. Barclays restated a buy rating and set a $43.00 price target on shares of Qiagen in a research report on Thursday, September 6th. Bank of America raised their price target on Qiagen from $38.00 to $39.00 and gave the company a neutral rating in a research report on Thursday, August 2nd. Finally, Deutsche Bank restated a buy rating on shares of Qiagen in a research report on Friday, August 3rd. One analyst has rated the stock with a sell rating, seven have issued a hold rating and six have assigned a buy rating to the stock. The stock currently has a consensus rating of Hold and an average target price of $38.88.

Shares of QGEN stock traded up $0.36 on Wednesday, reaching $34.36. The company’s stock had a trading volume of 660,991 shares, compared to its average volume of 966,598. The company has a current ratio of 5.07, a quick ratio of 4.59 and a debt-to-equity ratio of 0.69. Qiagen has a 12-month low of $30.20 and a 12-month high of $39.45.

Qiagen (NASDAQ:QGEN) last issued its quarterly earnings data on Tuesday, July 31st. The company reported $0.33 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.32 by $0.01. Qiagen had a return on equity of 11.74% and a net margin of 2.85%. The company had revenue of $377.20 million for the quarter, compared to the consensus estimate of $376.89 million. As a group, equities research analysts predict that Qiagen will post 1.34 earnings per share for the current year.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in QGEN. First Bank & Trust increased its holdings in shares of Qiagen by 156.0% in the second quarter. First Bank & Trust now owns 4,928 shares of the company’s stock worth $178,000 after buying an additional 3,003 shares during the period. Private Trust Co. NA purchased a new position in shares of Qiagen in the third quarter worth about $233,000. Lourd Capital LLC purchased a new position in shares of Qiagen in the third quarter worth about $250,000. Clinton Group Inc. purchased a new position in shares of Qiagen in the first quarter worth about $255,000. Finally, A.R.T. Advisors LLC purchased a new position in shares of Qiagen in the first quarter worth about $314,000. Institutional investors and hedge funds own 62.23% of the company’s stock.

Qiagen Company Profile

QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.

Featured Article: Asset Allocation Models, Which is Right For You?

Analyst Recommendations for Qiagen (NASDAQ:QGEN)

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.